Paul-Ehrlich-Institut

Dengue Fever Vac­cines

Name De­scrip­tion Mar­ket­ing Au­tho­ri­sa­tion Hold­er Kind of Vac­cine Li­cense Num­ber Li­cense Date Further Information

Deng­vax­ia

Tetrava­len­ter Dengue-Impf­stoff ­(lebend, at­tenuiert)

Für Men­schen zwis­chen 9 und 45 Jahren bes­timmt, die in der Ver­gan­gen­heit bere­its mit dem Dengue-Virus in­fiziert waren und in En­demiege­bi­eten leben

Sanofi Pas­teur, F-69007 Ly­on

Mono EU/1/18/1338 12.12.2018

EPAR

Hints

Disclaimer

The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.

The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.

As of: PEI announcement No. 477 in BAnz AT 16.02.2021 B7.

Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)

Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.

If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.

Updated: 01.03.2021